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Abstract Retinoic acid induced 1 (RAI1) is a protein of
uncertain mechanism of action which nevertheless has
been the focus of attention because it is a major contrib-
uting factor in several human developmental disorders
including Smith–Magenis and Potocki–Lupski syndromes.
Further, RAI1 may be linked to adult neural disorders with
developmental origins such as schizophrenia and autism.
The protein has been extensively examined in the rodent
but very little is known about its distribution in the human
central nervous system. This study demonstrated the pre-
sence of RAI1 transcript in multiple regions of the human
brain. The cellular expression of RAI1 protein in the
human brain was found to be similar to that described in
the mouse, with high levels in neurons, but not glia, of the
dentate gyrus and cornus ammonis of the hippocampus. In
the cerebellum, a second region of high expression, RAI1
was present in Purkinje cells, but not granule cells. RAI1
was also found in neurons of the occipital cortex. The
expression of this retinoic acid-induced protein matched
well in the hippocampus with expression of the retinoic
acid receptors. The subcellular distribution of human
neuronal RAI1 indicated its presence in both cytoplasm
and nucleus. Overall, human RAI1 protein was found to be
a highly expressed neuronal protein whose distribution
matches well with its role in cognitive and motor skills.
Keywords Transcription  Cytoplasmic  Smith–
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Introduction
The retinoic acid induced 1 (RAI1) gene is highly con-
served through mammalian evolution (Girirajan et al.
2005), while the corresponding protein is known to be
expressed at high levels in the heart and neuronal structures
(Toulouse et al. 2003). Its precise action is unclear, but
from its similarity to the transcriptional regulator TCF20
(also called stromelysin-1 platelet-derived growth factor-
responsive element binding protein, SPBP), it may be part
of a complex that regulates transcription and indeed it can
act as a transactivator (Seranski et al. 2001; Bi et al. 2004;
Carmona-Mora et al. 2010). A lot of interest surrounds
RAI1 because of its involvement in neurobehavioral dis-
orders in an intriguing dosage-sensitive manner (Carmona-
Mora and Walz 2010). Haploinsufficiency of the RAI1 gene
is associated with Smith–Magenis syndrome, a rare disor-
der that includes craniofacial, behavioural and neurological
signs including intellectual difficulties and sleep distur-
bance, as well as obesity (Slager et al. 2003; Girirajan et al.
2005). Many features of Smith–Magenis syndrome, origi-
nally described as resulting from an interstitial deletion in
chromosome 17p11.2 (Smith et al. 1986), are caused by the
loss of RAI1 which is located in this chromosomal region.
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In contrast, duplication of this same chromosomal region
results in another rare disorder, Potocki–Lupski syndrome,
whose features also include neurobehavioral difficulties
including features of autism, hypotonia and cardiovascular
anomalies. Again, the change in expression in RAI1 is
proposed to contribute to the disorder (Cao et al. 2013).
RAI1 is also associated with neurodevelopmental disorders
that are pervasive into adulthood including schizophrenia
(Toulouse et al. 2003) and autism (Carmona-Mora and
Walz 2010) as well as adult diseases such as Parkinson’s
disease (Do et al. 2011) and cerebellar ataxia (Hayes et al.
2000). The potential action of RAI1 as a regulator of
transcription is thus a key to normal function of the adult
brain.
RAI1 was first described as a retinoic acid-regulated
gene (Imai et al. 1995) from whence derived its name.
Retinoic acid is the bioactive metabolite of vitamin A,
acting through the ligand-gated nuclear receptor RAR, and
which influences motor function, memory and behaviour
(Shearer et al. 2012). The initial discovery of RAI1 came
from study of the P19 mouse embryonic carcinoma cell
line, showing that the expression of GT1, a splice variant of
RAI1, was significantly up-regulated after treatment with
retinoic acid to induce neuronal differentiation (Imai et al.
1995). The RAI1 promoter contains multiple retinoic acid
response elements (RAREs) in its promoter (Laperriere
et al. 2007) although there has been no description since
that time of regulation of RAI1 by retinoic acid.
Despite the growing knowledge of the role of RAI1 in
human neurological and psychiatric diseases, and its high
expression in brain (Toulouse et al. 2003), the distribution
of this protein in the human brain has yet to be described.
The present study aimed to investigate the expression of
RAI1 in human hippocampus, cortex and cerebellum, areas
likely involved in cognitive and motor functions of RAI1
neural expression (Elsea and Girirajan 2008). In these
regions, RAI1 was expressed in neurons, but not GFAP-
positive glia. The subcellular distribution of endogenous
RAI1 implied both nuclear and cytoplasmic localization,
differing from what has been described when RAI1 is
overexpressed in cell lines.
Methods
Tissue samples
The present study was approved by the Ethics Committee
of Universidade Metropolitana de Santos, SP, Brazil, and
by the Brazilian Health Research Committee on April 4th
2011, designated CONEP 16168, documents registered as
25000.169694/2010-18. Caudal human hippocampi, cere-
bellar and cerebral cortices were obtained from six male
individuals aged 55 years or less who did not present any
neurological or psychiatric disease and were collected
during necropsy procedures. Brains from individuals whose
death was related to head trauma, extensive infection or
toxic, anoxic or metabolic injuries were excluded from this
study. For immunohistochemistry, samples from the hip-
pocampus, cerebral cortex and cerebellum, measuring
typically 0.5 cm3, were fixed in 10 % phosphate-buffered
formalin within 24 h of death and processed into paraffin
wax blocks within the following 24 h. Further samples
from the same areas were collected in RNAlater RNA
Stabilization Reagent (Qiagen, Venlo, The Netherlands)
and stored at 4 C for qPCR.
Immunohistochemistry
Fluorescence immunohistochemistry was performed as
previously described in (Fragoso et al. 2012), adapted from
an earlier study (Makitie et al. 2010). Wax-embedded tis-
sue samples were sectioned at 7 lm, mounted onto A380-
bond slides (Electron Microscopy Sciences, Hatfield PA
19440, USA) and dried overnight at 37 C. Mounted sec-
tions were dewaxed in xylene and rehydrated through
decreasing ethanol concentrations (100, 95, 80 and 70 %).
Sections were then boiled for 10 min in sodium citrate
buffer, pH 6.0, allowed to cool on the bench for 20 min and
then washed in phosphate-buffered saline (PBS) pH 7.4,
containing 0.1 % Tween 20 (Sigma) and 1 % pooled
human serum (BioSera). Sections were then blocked for
1 h at room temperature in PBS containing 0.3 % Tween
20, 5 % normal goat serum, 5 % bovine serum albumin
and 5 % pooled human serum. The sections were next
incubated overnight at 4 C in primary antibody diluted in
blocking solution. The following primary antibodies were
used: mouse anti-Calbindin (1:500; Sigma, C9848), mouse
anti-GFAP (1:500; Sigma, G3893), chicken anti-MAP2
(1:1000; Abcam, ab5392), mouse anti-RAI1 (1:500; Santa
Cruz, D-11, sc-365065), rabbit anti-RAI1 (1:500; Abcam,
ab58658). After incubation, the slides were washed in
blocking solution, then incubated with a fluorescent sec-
ondary antibody (anti-rabbit 1:300, Invitrogen or anti
chicken 1:400, Jackson Immunoresearch) diluted in
blocking solution for 1 h at room temperature. Slides were
washed in blocking solution and incubated for 1 min with
10 % Sudan Black (Acros Organics) in 70 % isopropanol
to reduce autofluorescence (Schnell et al. 1999; Neumann
and Gabel 2002). The slides were then thoroughly washed
in distilled water and mounted with mounting medium
containing 1,4-diazabicyclo[2.2.2]octane (DABCO,
Sigma) and bisbenzimide (Sigma). The sections were
digitally imaged on a Zeiss Axio Imager M2 or a Zeiss
LSM710 confocal microscope on an inverted Axio
Observer Z1 stand.
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Quantitative polymerase chain reaction (qPCR)
qPCR was carried out as previously described (Fragoso
et al. 2012). Total RNA was extracted from tissue samples
using an Isolate RNA kit (Bioline) and cDNA synthesized
using a High Capacity RNA-to-cDNA kit (Applied Bio-
systems). qPCR was carried out using SensiMix SYBR
qPCR master mix (Bioline) and primers designed to
amplify human RAI1: forward: CCC AGG AGC ACT
GGG TGC ATG A, reverse: GCA GCT GGA ACA CAT
CAT GTC CAC G. The reference gene used was GAPDH,
forward: TCT TTT GCG TCG CCA GCC GA, reverse:
AGT TAA AAG CAG CCC TGG TGA CCA. Standard
curves and blank controls were run for both genes. Samples
(n = 3) were run on a LightCycler 480 thermal cycler
(Roche) and analysed using the efficiency-corrected
E-Method in Roche LightCycler 480 v1.5 software.
Regional differences in RAI1 expression levels were ana-
lysed by ANOVA, followed by post hoc t tests.
Western blotting
Human hippocampal protein was extracted in 0.01 M
phosphate buffer containing a protease inhibitor cocktail
(Sigma) using mechanical homogenization and 3 freeze–
thaw cycles. Homogenates were centrifuged for 10 min at
12,000 rpm at 4 C. Total protein levels in each sample
were quantified by the BCA assay (Pierce) and 50 lg total
protein per lane was loaded onto a NuPAGE Novex Tris–
acetate 3–8 % gradient mini-gel (Life Technologies). After
separation, proteins were transferred onto a Hybond ECL
nitrocellulose membrane (GE Healthcare) using a Mini
Trans-Blot Cell (Bio-Rad) for 4 h and loading was checked
with Ponceau S (Sigma). Membranes were probed with the
primary antibody that was to be used for anti-RAI1
immunohistochemistry, rabbit anti-RAI1 (1:1000; Abcam).
Labelled proteins were detected using a horseradish per-
oxidase (HRP)-conjugated anti-rabbit secondary antibody
(Sigma; 1:5000) and enhanced chemiluminescence (ECL;
Millipore), incubated for 5 min followed by exposure to
X-ray film (Thermo Fisher Scientific).
Subcellular fractionation
SH-SY5Y human neuroblastoma cells were grown in
Dulbecco’s Modified Eagle (DMEM)/F-12 medium (Gib-
co), containing 10 % fetal calf serum and penicillin–
streptomycin. Cells were harvested by trypsinization, pel-
leted by centrifugation and the medium discarded. Sub-
cellular fractionation was carried out immediately using a
protein and RNA isolation system kit (PARIS kit, Ambi-
on), following the manufacturer’s protocol. Briefly, the cell
pellet was resuspended in ice-cold PARIS cell fractionation
buffer and incubated on ice for 10 min to lyse the cells.
Nuclei were pelleted by centrifugation at 4 C (500g,
5 min), and then the cytoplasmic fraction was removed into
another tube and kept on ice. To reduce contamination by
cytoplasmic proteins, the nuclear pellet was washed by
gentle resuspension in cell fractionation buffer then cen-
trifuged again. The supernatant was discarded and the
nuclei were lysed in PARIS cell disruption buffer. A sec-
ond cell pellet obtained at the same time was homogenized
in ice-cold cell disruption buffer without fractionation to
give a whole cell lysate. Anti-RAI1 western blotting was
performed as described above. Western blotting against the
nuclear protein histone H3 (rabbit anti-histone H3,
1:10.000; Abcam) was performed to confirm that the
cytoplasmic fraction was free of nuclear contamination.
Results
The hippocampus and cerebellum are the regions of the
mouse brain in which RAI1 expression is strongest,
reflecting its role in learning and motor function (Bi et al.
2007). qPCR was used to investigate regional expression of
RAI1 in the human brain. Figure 1a shows that the human
cerebellum and hippocampus also show significant
expression of RAI1 transcript, together with the occipital
lobe of the cortex. RAI1 transcript levels were significantly
higher in the cerebellum versus the hippocampus and
occipital cortex. The distribution of the corresponding
RAI1 protein has not previously been investigated in the
human brain. To examine this, we employed an immuno-
histochemical method originally developed by Makitie
et al., providing sensitive and specific staining with very
little background autofluorescence (Makitie et al. 2010),
which is very effective with the formalin-fixed sections
used in this study (Fragoso et al. 2012). RAI1 distribution
in the human hippocampus was first examined using two
antibodies, each produced in a different species (rabbit and
mouse) to allow double labelling with a variety of neuronal
and glial markers. The distribution of labelling by these
two antibodies in the dentate gyrus was very similar
(Fig. 1b, c) and double labelling confirmed their staining
pattern was identical (Fig. 1d). Such strong expression of
RAI1 in the dentate gyrus is similar to what has been
shown in the mouse hippocampus (Bi et al. 2007). RAI1
was apparently present in both nucleus and cytoplasm with
the relative proportion in these compartments varying from
cell to cell. Confocal imaging demonstrated that nuclear
and cytoplasmic labelling was present in the same cell
(Fig. 1e) and a comparison was also made with the retinoic
acid receptor c, which colocalized to the same cells.
In the mouse, RAI1 is also expressed in the cornus
ammonis (CA) of the hippocampus (Bi et al. 2007) and this
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was the case in human CA1 (Fig. 2a). Mouse RAI1 was
described to be predominantly expressed in neurons (Bi
et al. 2007) and this was investigated in CA1 of the human
hippocampus by double labelling of RAI1 with MAP2 and
GFAP, specific markers of neurons and glia respectively.
RAI1 colocalised with MAP2, but not GFAP, demon-
strating specific neuronal expression (Fig. 2a, b). However,
it was noted that the subcellular localization of RAI1 was
not the same in all neurons. As illustrated in Fig. 2, RAI1
expression in some neurons was almost exclusively nuclear
(Fig. 2c), while in others it appeared to be present in both
nucleus and cytoplasm (Fig. 2d).
This apparent cytoplasmic localization of RAI1 was
surprising given that RAI1, when studied by induced
expression in cell lines, showed only nuclear expression
(Bi et al. 2005), and only truncated proteins lacking the
nuclear localization signal were present in the cytoplasm
(Carmona-Mora et al. 2010; Carmona-Mora et al. 2012).
Anti-RAI1 immunohistochemistry, however, using two
different antibodies showed apparent cytoplasmic and
nuclear labelling in the hippocampus (Fig. 1b, c). To fur-
ther examine whether endogenous RAI1 can be localized to
the cytoplasm, we studied endogenous RAI1 in the SH-
SY5Y human neuroblastoma cell, in which RAI1 expres-
sion has not previously been investigated. This cell line
was chosen as a human neuroblastoma cell line and so
showing some properties of human neural cells. In this cell
line, RAI1 was predominantly found in the cytoplasm
(Fig. 3a, a0). Western blotting was used to investigate RAI1
protein expression and a band was evident with a molecular
weight similar to the approximately 260 kDa previously
reported for RAI1 protein (Carmona-Mora et al. 2010)
(Fig. 3b). To confirm that the cytoplasmic immunolabel-
ling for RAI1 was an accurate reflection of the protein
distribution in SH-SY5Y cells, nuclear and cytoplasmic
fractions were separated using a PARIS kit (Ambion). The
whole cell and cytoplasmic fractions were found to contain
RAI1 and this fraction was demonstrated to be free of any
nuclear contamination using antibodies to the nuclear
protein histone H3 (Fig. 3c).
Figure 1a showed the cerebellum and cerebral cortex to
be regions of RAI1 transcript expression. In the mouse
cerebellum, RAI1 is strongly expressed in the Purkinje cell
layer (Bi et al. 2007). Similarly, RAI1 was very strongly
bFig. 1 Expression of RAI1 mRNA transcript in regions of the human
brain and immunohistochemistry for RAI1 in the dentate gyrus. qPCR
analysis of RAI1 in the human cerebellum, hippocampus and occipital
lobe of the cerebral cortex indicated its presence in all these regions
(a). Cerebellar and occipital lobe expression is shown relative to
hippocampal expression. Expression was significantly greater in the
cerebellum compared to the hippocampus (P \ 0.05; ANOVA
followed by post hoc t test) and the occipital lobe (P \ 0.01). Mouse
(b) and rabbit (c) anti-RAI1 antibodies were compared and found to
show similar strong expression in the human dentate gyrus and, when
combined for double labelling, were found to be identical in
distribution in both nucleus and cytoplasm in cells of the dentate
gyrus, although expression varied between individual neurons (d).
Confocal analysis of RAI1 expression also indicated expression of
RAI1 in nuclei and cytoplasm, and expression in the same cells as
RARc (e). Scale bars 50 lm in b, c; 25 lm in d, e
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expressed in human Purkinje cells (Fig. 4a), apparently in
both the nucleus, the cell body and in the thicker dendritic
branches. As in the mouse, RAI1 was absent from the
cerebellar granule neurons (Fig. 4b). The low expression of
MAP2 in the cerebellar granule neurons evident in Fig. 4b
has previously been reported (Di Stefano et al. 2001). A
second region of neuronal RAI1 expression was found to
be the cerebral cortex and RAI1 protein was apparently
present in both cytoplasm and nucleus of MAP2-positive
neurons in the occipital cortex (Fig. 4c).
RAI1 is named after its retinoic acid inducibility and,
given our recent finding of strong expression of the reti-
noic acid receptors (RARs) in human hippocampal neu-
rons (Fragoso et al. 2012), the relative distribution of
RAI1 was compared with the three subclasses of these
receptors. As previously found, RARa and RARc were
predominantly in the nucleus (Fig. 5a, c) and RARb in
both nucleus and cytoplasm (Fig. 5b), but most cells that
express RAI1 also express the retinoic acid receptors
(Fig. 5a–c).
Fig. 2 RAI1 expression in nucleus and cytoplasm of neurons in the
hippocampal CA1 subfield. Double labelling of rabbit anti-RAI1 with
MAP2 antibodies demonstrates expression of RAI1 in neurons of
CA1 (a) while labelling with GFAP shows its absence in glia in this
region (b). Of note was the differing subcellular distribution of
RAI1—using the rabbit anti-RAI1 antibody, expression was confined
to the nucleus in some cells (c), whereas RAI1 was present in both the
nucleus and cytoplasm of others (d). Scale bars 25 lm
Fig. 3 Expression of RAI1 in the cytoplasm of human SH-SY5Y
cells. The expression of RAI1 in the cytoplasm was examined in a cell
line in which RAI1 was apparently present in both the cytoplasm and
nucleus (a and higher magnification view of three cells in aı). The
rabbit anti-RAI1 detected a protein of approximately 280 kDa by
western blotting (b). When SH-SY5Y cells were lysed and separated
into nuclear and cytoplasmic fractions, the 280 kDa band was
detected by western blotting in the whole cell (WCL) and cytosolic
(CYTO) fraction but very little was present in the nuclear (NUC)
fraction (c). The cytosolic fraction was uncontaminated by the nuclear
fraction as indicated by the absence of the 17 kDa histone H3 protein
(c). Scale bar in (a) 25 lm
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Discussion
Interest in RAI1 has rapidly increased in the past few years
because of its association with disease. Deletion of the
chromosomal region 17p11.2 results in Smith–Magenis
syndrome and haploinsufficiency of RAI1 makes a major
contribution to the resulting craniofacial abnormalities,
behavioural problems and mental retardation. The reci-
procal duplication of this region leads to Potocki–Lupski
syndrome, which similarly results in mental retardation,
Fig. 4 Expression of RAI1 in
the human cerebellum and
cerebral cortex. RAI1 was
strongly expressed in cerebellar
Purkinje cells (PC) and was
observed in both the nucleus
and the cytoplasm of the larger
dendrites (a, b), but was absent
from cerebellar granule neurons
(GC in b). RAI1 was present in
cells of layers II to IV of the
occipital cortex (c). Scale bars
25 lm
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but also hyperactivity and some autism-like features. This
study shows, for the first time, the distribution of RAI1
protein in the adult human brain. RAI1 was found to be
present in the majority of neurons in both hippocampus and
cortex, as expected from earlier studies showing the human
brain to be the tissue with highest RAI1 expression and
mRNA to be present in all brain regions examined except
for the corpus callosum (Toulouse et al. 2003), similar to
the distribution in the mouse (Imai et al. 1995). As found in
the mouse (Bi et al. 2007), we found that RAI1 is absent
Fig. 5 Colocalization of RAI1
with the retinoic acid receptors
(RARs). In the hippocampal
CA1 subfield, RAI1 was
expressed in cells that also
express RARa, which is
predominantly in the nucleus
(a), RARb, present in both the
nucleus and cytoplasm (b) and
RARc, which is mainly nuclear
in expression (c). Scale bars
25 lm
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from glial cells in the hippocampus and is strongly
expressed in cerebellar Purkinje cells but not granule cells.
The subcellular distribution of RAI1 was suggestive of
expression of RAI1 in both the nucleus and cytoplasm.
The RAI1 protein has multiple putative nuclear locali-
zation sequences (NLS) (Slager et al. 2003; Carmona-Mora
and Walz 2010) and when expressed in a cell line is
transported into the nucleus (Carmona-Mora et al. 2010),
while mutant forms of RAI1 lacking the NLS localize to
the cytoplasm (Bi et al. 2005; Carmona-Mora et al. 2010;
Carmona-Mora et al. 2012). Several studies points to RAI1
functioning as a transactivator (Seranski et al. 2001; Bi
et al. 2004; Carmona-Mora et al. 2010) and it induces
expression of the central circadian circadian locomotor
output cycles kaput (CLOCK) gene while haploinsuffi-
ciency of RAI1 disrupts many circadian genes (Williams
et al. 2012). RAI1’s regulation of BDNF in the hypothal-
amus may contribute to the hyperphagia and obesity seen
in Smith–Magenis syndrome (Burns et al. 2010) and hap-
loinsufficiency of RAI1 results in abnormal expression of a
number of genes associated with obesity, including pro-
opiomelanocortin (POMC). Major gene changes in the
hypothalamus in this condition also include alterations in
growth hormone together with a number of homeobox-
containing transcription factors (Burns et al. 2010).
These results point to RAI1’s presence in the nucleus to
regulate transcription. When transfected into cell lines it
localizes to the nucleus and is associated with chromatin
(Bi et al. 2005, 2010; Carmona-Mora et al. 2012) while a
study of lymphoblastoid cells from normal or Smith–
Magenis patients indicated expression in the nucleus
(Carmona-Mora et al. 2012). Although the smallest pre-
dicted splicing variant of RAI1 lacks the NLS and localizes
to the cytoplasm (Burns et al. 2010), this is not the large
form of RAI1 seen by western blotting in this study.
However, it is possible that the protein conformation of this
smaller form is such that it is only recognized by antibody
in fixed cells and not once denatured for gel electrophoresis
and western blotting. It is of interest though that the ori-
ginal identification of the endogenous RAI1 gene, in the
mouse P19 embryonic carcinoma cell line (Imai et al.
1995), also described the protein to be present in the
cytoplasm of neurons of the adult mouse brain and thus a
cytoplasmic role was proposed. It is possible that this is
also the smaller form of RAI1. This present study suggests
that forms of endogenous RAI1 in the human brain can be
expressed in both the nucleus and cytoplasm in neurons
suggesting a role for this cytoplasmic expression, even if
just to inhibit RAI1’s nuclear action to regulate transcrip-
tion. The relative intensity of expression of RAI1 in the
nucleus and cytoplasm differed even between neurons of
the same type implying a variance between these cells that
may reflect, for instance, functional activity.
The inducibility by retinoic acid that gives RAI1 its
name was reflected in the parallels in this study between
the neuronal expression of RAI1 and overlap with retinoic
acid receptor expression. Retinoic acid can regulate RAI1
(Imai et al. 1995) and there is a retinoic acid response
element (RARE) just upstream of exon 1 (Toulouse et al.
2003); an analysis of the RAI1 promoter found three DR2-
type RAREs which are bound by retinoic acid receptors as
determined by chromatin immunoprecipitation assay
(Laperriere et al. 2007). In the contrary direction, there
may be some element of retinoid signalling downstream of
RAI1 action. Cell line analysis of genes altered by hap-
loinsufficiency of RAI1 found retinoid x receptor beta
(RXRB) as one of the ten main genes up-regulated and also
proposed an interrelatedness in phenotype with several
diseases that included DiGeorge syndrome and fragile X
syndrome (Girirajan et al. 2009). Both of these develop-
mental disorders have been associated with abnormal ret-
inoic acid signalling (Guris et al. 2006; Soden and Chen
2010). The interrelationship between retinoic acid, its
receptors (RARs) and RAI1 are not yet understood. Given
that RAI1 promotes transcription (Carmona-Mora et al.
2012) and may act as transcriptional co-activator like its
homologue TCF20 [also called SPBP (Darvekar et al.
2012)], perhaps RAI1 and the RARs themselves interact.
The action of nuclear receptors, such as the androgen and
oestrogen receptors, as well as the RARs, are tightly con-
trolled by co-activators and co-repressors (Rochette-Egly
and Germain 2009). It is of note that TCF20 acts as a co-
activator for the androgen receptor (Elvenes et al. 2011)
but is a repressor of phosphorylated estrogen receptor
(Gburcik et al. 2005).
The findings of this report provide the first demonstra-
tion of high expression of the essential protein RAI1 in
neurons of several regions of the human brain. Its presence
in both nucleus and cytoplasm may indicate shuttling, and
so control, of this protein whose function includes regula-
tion of transcription. Alternatively, different splice variants
may be localized to the two subcellular compartments. The
coexpression of RAI1 with the retinoic acid receptors
supports a functional relationship between these two tran-
scription regulatory proteins.
Acknowledgments Funding was provided by the Wellcome Trust
and Tenovus Scotland. Prof Fragoso is the recipient of a Post Doctoral
Science without Borders grant from the Brazilian National Council
for Scientific and Technological Development (CNPq, 237450/2012-
7). We also thank Aberdeen Proteomics for assistance with the
western blots as well as the Microscopy and Histology Core Facility
at the University of Aberdeen for confocal microscopy.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
1202 Brain Struct Funct (2015) 220:1195–1203
123
References
Bi W, Saifi GM, Shaw CJ, Walz K, Fonseca P, Wilson M, Potocki L,
Lupski JR (2004) Mutations of RAI1, a PHD-containing protein,
in nondeletion patients with Smith–Magenis syndrome. Hum
Genet 115(6):515–524. doi:10.1007/s00439-004-1187-6
Bi W, Ohyama T, Nakamura H, Yan J, Visvanathan J, Justice MJ,
Lupski JR (2005) Inactivation of Rai1 in mice recapitulates
phenotypes observed in chromosome engineered mouse models
for Smith–Magenis syndrome. Hum Mol Genet 14(8):983–995.
doi:10.1093/hmg/ddi085
Bi W, Yan J, Shi X, Yuva-Paylor LA, Antalffy BA, Goldman A, Yoo
JW, Noebels JL, Armstrong DL, Paylor R, Lupski JR (2007)
Rai1 deficiency in mice causes learning impairment and motor
dysfunction, whereas Rai1 heterozygous mice display minimal
behavioral phenotypes. Hum Mol Genet 16(15):1802–1813.
doi:10.1093/hmg/ddm128
Burns B, Schmidt K, Williams SR, Kim S, Girirajan S, Elsea SH
(2010) Rai1 haploinsufficiency causes reduced Bdnf expression
resulting in hyperphagia, obesity and altered fat distribution in
mice and humans with no evidence of metabolic syndrome. Hum
Mol Genet 19(20):4026–4042. doi:10.1093/hmg/ddq317
Cao L, Molina J, Abad C, Carmona-Mora P, Cardenas Oyarzo A,
Young JI, Walz K (2013) Correct developmental expression
level of Rai1 in forebrain neurons is required for control of body
weight, activity levels and learning and memory. Hum Mol
Genet. doi:10.1093/hmg/ddt568
Carmona-Mora P, Walz K (2010) Retinoic acid induced 1, RAI1: a
dosage sensitive gene related to neurobehavioral alterations
including autistic behavior. Curr Genomics 11(8):607–617.
doi:10.2174/138920210793360952
Carmona-Mora P, Encina CA, Canales CP, Cao L, Molina J, Kairath
P, Young JI, Walz K (2010) Functional and cellular character-
ization of human retinoic acid induced 1 (RAI1) mutations
associated with Smith–Magenis Syndrome. BMC Mol Biol
11:63. doi:10.1186/1471-2199-11-63
Carmona-Mora P, Canales CP, Cao L, Perez IC, Srivastava AK,
Young JI, Walz K (2012) RAI1 transcription factor activity is
impaired in mutants associated with Smith–Magenis syndrome.
PLoS One 7(9):45155. doi:10.1371/journal.pone.0045155
Darvekar S, Johnsen SS, Eriksen AB, Johansen T, Sjottem E (2012)
Identification of two independent nucleosome-binding domains
in the transcriptional co-activator SPBP. Biochem J
442(1):65–75. doi:10.1042/BJ20111230
Di Stefano G, Casoli T, Fattoretti P, Gracciotti N, Solazzi M, Bertoni-
Freddari C (2001) Distribution of map2 in hippocampus and
cerebellum of young and old rats by quantitative immunohisto-
chemistry. J Histochem Cytochem Off J Histochem Soc
49(8):1065–1066
Do CB, Tung JY, Dorfman E, Kiefer AK, Drabant EM, Francke U,
Mountain JL, Goldman SM, Tanner CM, Langston JW, Wojcicki
A, Eriksson N (2011) Web-based genome-wide association study
identifies two novel loci and a substantial genetic component for
Parkinson’s disease. PLoS Genet 7(6):1002141. doi:10.1371/
journal.pgen.1002141
Elsea SH, Girirajan S (2008) Smith–Magenis syndrome. Eur J Hum
Genet EJHG 16(4):412–421. doi:10.1038/sj.ejhg.5202009
Elvenes J, Thomassen EI, Johnsen SS, Kaino K, Sjottem E, Johansen
T (2011) Pax6 represses androgen receptor-mediated transacti-
vation by inhibiting recruitment of the coactivator SPBP. PLoS
One 6(9):24659. doi:10.1371/journal.pone.0024659
Fragoso YD, Shearer KD, Sementilli A, de Carvalho LV, McCaffery
PJ (2012) High expression of retinoic acid receptors and
synthetic enzymes in the human hippocampus. Brain Struct
Funct 217(2):473–483. doi:10.1007/s00429-011-0359-0
Gburcik V, Bot N, Maggiolini M, Picard D (2005) SPBP is a
phosphoserine-specific repressor of estrogen receptor alpha. Mol
Cell Biol 25(9):3421–3430. doi:10.1128/MCB.25.9.3421-
3430.2005
Girirajan S, Elsas LJ, Devriendt K, Elsea SH (2005) RAI1 variations
in Smith–Magenis syndrome patients without 17p11.2 deletions.
J Med Genet 42(11):820–828. doi:10.1136/jmg.2005.031211
Girirajan S, Truong HT, Blanchard CL, Elsea SH (2009) A functional
network module for Smith–Magenis syndrome. Clin Genet
75(4):364–374. doi:10.1111/j.1399-0004.2008.01135.x
Guris DL, Duester G, Papaioannou VE, Imamoto A (2006) Dose-
dependent interaction of Tbx1 and Crkl and locally aberrant RA
signaling in a model of del22q11 syndrome. Dev Cell 10(1):81–92
Hayes S, Turecki G, Brisebois K, Lopes-Cendes I, Gaspar C, Riess O,
Ranum LP, Pulst SM, Rouleau GA (2000) CAG repeat length in
RAI1 is associated with age at onset variability in spinocerebel-
lar ataxia type 2 (SCA2). Hum Mol Genet 9(12):1753–1758
Imai Y, Suzuki Y, Matsui T, Tohyama M, Wanaka A, Takagi T
(1995) Cloning of a retinoic acid-induced gene, GT1, in the
embryonal carcinoma cell line P19: neuron-specific expression
in the mouse brain. Brain Res Mol Brain Res 31(1–2):1–9
Laperriere D, Wang TT, White JH, Mader S (2007) Widespread Alu
repeat-driven expansion of consensus DR2 retinoic acid response
elements during primate evolution. BMC Genom 8:23. doi:10.
1186/1471-2164-8-23
Makitie LT, Kanerva K, Polvikoski T, Paetau A, Andersson LC
(2010) Brain neurons express ornithine decarboxylase-activating
antizyme inhibitor 2 with accumulation in Alzheimer’s disease.
Brain Pathol 20(3):571–580. doi:10.1111/j.1750-3639.2009.
00334.x
Neumann M, Gabel D (2002) Simple method for reduction of
autofluorescence in fluorescence microscopy. J Histochem Cy-
tochem Off J Histochem Soc 50(3):437–439
Rochette-Egly C, Germain P (2009) Dynamic and combinatorial
control of gene expression by nuclear retinoic acid receptors
(RARs). Nucl Recept Signal 7:e005. doi:10.1621/nrs.07005
Schnell SA, Staines WA, Wessendorf MW (1999) Reduction of
lipofuscin-like autofluorescence in fluorescently labeled tissue.
J Histochem Cytochem Off J Histochem Soc 47(6):719–730
Seranski P, Hoff C, Radelof U, Hennig S, Reinhardt R, Schwartz CE,
Heiss NS, Poustka A (2001) RAI1 is a novel polyglutamine
encoding gene that is deleted in Smith–Magenis syndrome
patients. Gene 270(1–2):69–76
Shearer KD, Stoney PN, Morgan PJ, McCaffery PJ (2012) A vitamin
for the brain. Trends Neurosci 35(12):733–741. doi:10.1016/j.
tins.2012.08.005
Slager RE, Newton TL, Vlangos CN, Finucane B, Elsea SH (2003)
Mutations in RAI1 associated with Smith–Magenis syndrome.
Nat Genet 33(4):466–468
Smith AC, McGavran L, Robinson J, Waldstein G, Macfarlane J,
Zonona J, Reiss J, Lahr M, Allen L, Magenis E (1986) Interstitial
deletion of (17) (p11.2p11.2) in nine patients. Am J Med Genet
24(3):393–414. doi:10.1002/ajmg.1320240303
Soden ME, Chen L (2010) Fragile X protein FMRP is required for
homeostatic plasticity and regulation of synaptic strength by
retinoic acid. J Neurosci 30(50):16910–16921. doi:10.1523/
JNEUROSCI.3660-10.2010
Toulouse A, Rochefort D, Roussel J, Joober R, Rouleau GA (2003)
Molecular cloning and characterization of human RAI1, a gene
associated with schizophrenia. Genomics 82(2):162–171
Williams SR, Zies D, Mullegama SV, Grotewiel MS, Elsea SH (2012)
Smith–Magenis syndrome results in disruption of CLOCK gene
transcription and reveals an integral role for RAI1 in the
maintenance of circadian rhythmicity. Am J Hum Genet
90(6):941–949. doi:10.1016/j.ajhg.2012.04.013
Brain Struct Funct (2015) 220:1195–1203 1203
123
